Protein Discovery and Engineering

Discovering and engineering novel CRISPR systems and technologies

We are addressing the current challenges of CRISPR-Cas systems such as in vivo delivery and expanding the scope of disease applications by applying our proprietary discovery and engineering platform to identify novel Cas proteins and associated technologies.

How We Do It

Discovery and Engineering Pipeline

Our protein discovery and engineering process starts with an in-silico analysis from one of the largest and growing metagenomic databases (including exclusive sample data) using proprietary AI algorithms to search for novel CRISPR systems and technologies. High-throughput wet-lab screening is then used to identify protein characteristics and function followed by high throughput engineering to realize our technology’s full potential. Together, the newly identified Cas proteins and associated technologies create a diverse and growing portfolio that enables new CRISPR applications to meet unmet patient needs.

  • Microbial DNA is sequenced from environmental samples
  • Metagenomic sequences are compiled in massive databases
  • Algorithms are used to search databases for sequences indicative of CRISPR systems and associated technologies
  • Systems are synthesized and tested in the lab
  • Systems enhanced by protein engineering

Our Technology

CRISPR Portfolio

We have identified Cas enzymes and associated technologies that have the ability to perform a variety of edit types as well as have unique properties including ultracompact size, increased temperature stability, faster reaction kinetics, and alternative PAM sequences for more flexible targeting.

These properties can be leveraged to realize the full potential of genetic medicine to perform a wide variety of edits in-vivo for potentially curative therapies that address major unmet patient needs.

Modality Portfolio

Our ultracompact CRISPR-Cas enzymes provide a scaffold to expand beyond double-stranded breaks in vivo.

  • Nuclease

    Ultracompact versions of CRISPR that make double stranded breaks to inactivate genes

  • Epigenetic Editing

    A platform technology that uses epigenetic modifications to silence genes

  • Base Editing

    A platform technology that makes a single-letter change to convert A to G or C to T

  • RT Editing

    A platform technology that makes versatile RNA-encoded insertions, deletions or substitutions

We Choose the Best Modality for Each Disease, Driven by Disease Biology


Let’s work together

Mammoth is committed to advancing science internally and through collaborations in the service of its mission to discover, develop and commercialize drugs to improve the lives of patients. Please get in touch with us below if you would like to join us on our journey.

Contact Us